Several other analysts also recently commented on BLFS. ValuEngine raised shares of BioLife Solutions from a hold rating to a buy rating in a report on Thursday, January 31st. Zacks Investment Research downgraded shares of BioLife Solutions from a buy rating to a hold rating in a report on Tuesday, March 12th. Finally, Northland Securities reaffirmed a buy rating and issued a $18.00 price objective on shares of BioLife Solutions in a report on Monday, May 13th. Seven investment analysts have rated the stock with a buy rating, BioLife Solutions presently has a consensus rating of Buy and an average price target of $17.80.
NASDAQ:BLFS opened at $17.53 on Wednesday. The company has a market cap of $329.55 million, a price-to-earnings ratio of 125.21 and a beta of 1.53. BioLife Solutions has a twelve month low of $9.15 and a twelve month high of $26.35. The company has a current ratio of 14.50, a quick ratio of 12.99 and a debt-to-equity ratio of 0.02.
In other news, Director Joseph C. Schick sold 22,053 shares of the company’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $17.11, for a total value of $377,326.83. Following the sale, the director now directly owns 18,928 shares of the company’s stock, valued at approximately $323,858.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Todd Berard sold 3,000 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $16.67, for a total transaction of $50,010.00. Following the completion of the sale, the vice president now directly owns 44,074 shares in the company, valued at $734,713.58. The disclosure for this sale can be found here. Insiders sold a total of 105,917 shares of company stock worth $1,849,185 over the last ninety days. Insiders own 38.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Roubaix Capital LLC acquired a new position in shares of BioLife Solutions in the 1st quarter valued at $809,000. Vanguard Group Inc. lifted its stake in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after purchasing an additional 134,869 shares during the period. Vanguard Group Inc lifted its stake in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after purchasing an additional 134,869 shares during the period. BlackRock Inc. raised its position in BioLife Solutions by 199.8% during the third quarter. BlackRock Inc. now owns 153,610 shares of the medical equipment provider’s stock worth $2,688,000 after acquiring an additional 102,364 shares during the period. Finally, GSA Capital Partners LLP raised its position in BioLife Solutions by 21.1% during the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 2,400 shares during the period. Hedge funds and other institutional investors own 44.02% of the company’s stock.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Recommended Story: Convertible Shares
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.